Breast Neoplasm

In a panel of 47 breast cancer cell lines, HER2 overexpressing cells were among those more sensitive to CDK4/6 inhibitor Palbociclib (PD0332991). In the trastuzumab sensitive cell line Bt474, palbocic… (full text at CIViC)

PMID 19874578 · Finn et al., 2009 · Open in CIViC

In 5 trastuzumab resistant HER2 overexpressing breast cancer cell lines, combination of the pan-PI3K inhibitor XL147 (pilaralisib) and trastuzumab treatment induced cell death to similar or greater le… (full text at CIViC)

PMID 23204226 · Chakrabarty et al., 2013 · Open in CIViC

In this phase II, randomized, double-blinded, controlled study, 612 patients with HER2-positive metastatic breast cancer previously treated with trastuzumab, pertuzumab, and trastuzumab emtansine. The… (full text at CIViC)

PMID 31825569 · Murthy et al., 2020 · Open in CIViC

In a real-world cohort of metastatic breast cancer (n = 63; 30 HER2-positive, 33 HER2-low), patients received HER2-targeted antibody-drug conjugates (trastuzumab deruxtecan (68.25%), disitamab vedotin… (full text at CIViC)

PMID 39806366 · Huang et al., 2025 · Open in CIViC

Neratinib-resistant cell lines were established by stepwise escalation method and high concentration method in breast cancer cell line BT-474 and lung cancer cell line H2170 with HER2 amplification. E… (full text at CIViC)

PMID 31856375 · Takeda et al., 2020 · Open in CIViC

In MCF10A cell lines, the D769H mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In MCF10A cell lines, the D769Y mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

Cell proliferation analysis of NIH 3T3 cells harboring the G309A variation exhibit an increase of colony formation in soft agar compared with a wild-type ERBB2 and cells with ERBB2 D845A kinase-inacti… (full text at CIViC)

PMID 22908275 · Greulich et al., 2012 · Open in CIViC

In MCF10A cell lines, the G309A mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In MCF10A cell lines, the in-frame insertion of a three amino acids at position (GSP) 780 was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

The confirmed variants Ile654Val, Ile655Val and Ala1170Pro were analysed in subsequent epidemiological studies on familial breast cancer risk. While Ala1170Pro resides within a C-terminally located re… (full text at CIViC)

PMID 15550452 · Frank et al., 2005 · Open in CIViC

K753E was identified in 6/338 HER2-positive tumors (2/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 K753E were more resistant to lapatinib treatment in comparison to HER2 WT … (full text at CIViC)

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

3/18 metastatic HER2-positive breast cancers had the K755S mutation after one year of adjuvant trastuzumab. K755S was undetectable in the corresponding primary tumors. In vitro experiments showed that… (full text at CIViC)

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

L768S was identified in 1/338 HER2-negative tumors (1/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 L768S were sensitive to lapatinib treatment.

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

K753E was identified in 6/338 HER2-positive tumors (2/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 K753E were more resistant to trastuzumab treatment than HER2 WT cells. 2/1… (full text at CIViC)

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC)

PMID 23220880 · Bose et al., 2013 · Open in CIViC

The L755S mutation was shown to confer resistance to lapatinib in MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

A series of HER2 (ERBB2) mutations (G309A, D769H, D769Y, V777L, P780ins, V824I, R678Q, R896C, del755-759, and L755S) were functionally characterized and tested for sensitivity to lapatinib or neratini… (full text at CIViC)

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In MCF10A cell lines retrovirally transduced with wildtype or mutant ERBB2, cells expressing the in-frame deletion of amino acids 755-759 were shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

MCF10A cells transduced with ERBB2 harboring an L755W mutation were sensitive to the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

L768S was identified in 1/338 HER2-negative tumors (1/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 L768S were sensitive to trastuzumab treatment.

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

A 54-year-old female with heavily pre-treated estrogen and progesterone receptor positive, ERBB2 nonamplified lobular metastatic breast carcinoma harboring ERBB2 L869R mutation exhibited almost comple… (full text at CIViC)

PMID 28274957 · Hanker et al., 2017 · Open in CIViC

16 patients with HER2-mutated metastatic breast cancer were treated with neratinib monotherapy. Of these 16 patients, 14 had known-activating mutations and 2 had mutations of unknown significance. Fiv… (full text at CIViC)

PMID 28679771 · Ma et al., 2017 · Open in CIViC

The antitumor activity of lapatinib in the CNS observed in the previous, smaller, phase 2 study, and confirmed in the present study, seems comparable to that observed outside of the CNS. As first-line… (full text at CIViC)

PMID 19228746 · Lin et al., 2009 · Open in CIViC

Our findings suggest that the combination of lapatinib plus capecitabine is active for the treatment of previously untreated brain metastases in patients with HER2-positive metastatic breast cancer. T… (full text at CIViC)

PMID 23122784 · Bachelot et al., 2013 · Open in CIViC

MCF10A cells transduced with ERBB2 harboring an R678Q mutation were sensitive to lapatinib and the irreversible kinase inhibitor neratinib in an matrigel colony forming assay.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In MCF10A cell lines, the R896C mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In this phase II NCI-MATCH trial, a patient with ER+ lobular breast cancer with ERBB2 S310F mutation was treated with afatinib. A 51% reduction of RECIST target lesions was reported after six cycles, … (full text at CIViC)

PMID 35939768 · Bedard et al., 2022 · Open in CIViC

Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. In the control group (n = 936), higher serum HER2 (sHER2) was associated with w… (full text at CIViC)

PMID 26811533 · Lee et al., 2016 · Open in CIViC

Serum and tissue levels of HER2 (ERBB2) were analyzed in 1,902 breast cancer patients treated with lapatinib or control. Serum HER2 (sHER2) levels measured by ELISA were higher in patients with HER2 a… (full text at CIViC)

PMID 26811533 · Lee et al., 2016 · Open in CIViC

Efficacy of afatinib at reducing phosphorylation of key proteins was evaluated by western blot. NR6 mouse fibroblast cells transduced to co-express ERBB2 L869R and T798I responded to afatinib treatmen… (full text at CIViC)

PMID 28274957 · Hanker et al., 2017 · Open in CIViC

A 54-year-old female with estrogen and progesterone receptor positive, ERBB2 non-amplified lobular heavily pretreated metastatic breast carcinoma harboring ERBB2 L869R, a CDH1 truncating mutation, ERB… (full text at CIViC)

PMID 28274957 · Hanker et al., 2017 · Open in CIViC

V773L was identified in 2/338 HER2-negative tumors (2/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 V773L were sensitive to trastuzumab treatment.

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

V773L was identified in 2/338 HER2-negative tumors (2/1248 total tumors). In vitro studies showed that MCF10A cells with HER2 V773L were sensitive to lapatinib treatment.

PMID 27697991 · Zuo et al., 2016 · Open in CIViC

In this phase II NCI-MATCH trial, a patient with ER+ invasive ductal breast cancer with ERBB2 V777L mutation was treated with afatinib. A RECIST response was reported in the patient, however, it wasn'… (full text at CIViC)

PMID 35939768 · Bedard et al., 2022 · Open in CIViC

In MCF10A cell lines, the V777L mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

In MCF10A cell lines, the V842I mutation was shown to be sensitive to neratinib.

PMID 23220880 · Bose et al., 2013 · Open in CIViC

A 46-year old woman with metastatic breast cancer after 2 lines of systemic therapy (doxorubicin/cyclophosphamide and docetaxel/capecitabine) was found to harbor a ERBB3 G284R mutation in the primary … (full text at CIViC)

PMID 25953157 · Bidard et al., 2015 · Open in CIViC

Women with primary breast cancer were randomized (3:1) to 10 to 14 days of preoperative lapatinib or placebo in a multicenter phase II trial. Biopsies pre-/posttreatment were analyzed for Ki67, apopto… (full text at CIViC)

PMID 25398453 · Leary et al., 2015 · Open in CIViC

In a phase 1/2 trial, HER3 positive (IHC 2+/3+) advanced breast cancer were treated wtih HER3 targeting antibody-drug conjugate U3-1402. A total of 34 patients positive breast cancer, 3 were HER2 posi… (full text at CIViC)

Open in CIViC

Preventing HER4 cleavage by a γ-secretase inhibitor and inhibiting HER4 tyrosine kinase activity by neratinib decreased trastuzumab-induced HER4 nuclear translocation and enhanced trastuzumab response… (full text at CIViC)

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC

ERBB4 protein expression was identified in breast cancer cell lines with acquired lapatinib resistance. Genetic ablation of ERBB4 (not ERBB1-3) led to apoptosis in trastuzumab- and lapatinib resistant… (full text at CIViC)

PMID 25590338 · Canfield et al., 2015 · Open in CIViC

HER4 nuclear translocation was identified as a mediator of trastuzumab resistance in HER2 positive breast cancer cell lines. Increased nuclear staining was also identified in xenograft and patient sam… (full text at CIViC)

PMID 25153719 · Mohd Nafi et al., 2014 · Open in CIViC